Astaxanthin prevents bone loss in osteoporotic rats with palmitic acid through suppressing oxidative stress.
Redox Rep
; 29(1): 2333096, 2024 Dec.
Article
en En
| MEDLINE
| ID: mdl-38623993
ABSTRACT
OBJECTIVES:
The study aimed to assess the role of Astaxanthin (ATX) in palmitic acid(PA) -induced bone loss in Ovariectomized(OVX) rats.METHODS:
In the OVX rat model, we observed that PA affects bone metabolism and accelerates bone loss. Additionally, treatment with ATX was able to suppress the deleterious effects of PA and a simultaneous decrease in serum MDA levels and an increase in SOD was observed.RESULTS:
In addition, rats treated with ATX were observed to have significantly increased bone mass and elevated activity of SIRT1 and SOD2 in bone tissue. When MC3T3-E1 and RAW264.7 cells induced osteoblast and osteoclast differentiation, the ATX intervention was able to significantly restore the restriction of osteogenic differentiation and the up-regulation of osteoclast differentiation with PA therapy. Furthermore, we confirm that PA damage to cells is caused by increased oxidative stress, and that ATX can target and modulate the activity of SIRT1 to regulate the levels of oxidative stress in cells.CONCLUSION:
Summarizing, ATX may inhibit PA-induced bone loss through its antioxidant properties via the SIRT1 signaling pathway.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Osteoporosis
Límite:
Animals
Idioma:
En
Revista:
Redox Rep
Asunto de la revista:
BIOQUIMICA
/
METABOLISMO
Año:
2024
Tipo del documento:
Article